Domain antibodies: Proteins for therapy

Trends in Biotechnology

Volumn 21, Issue 11, 2003, Pages 484-490

  Holt, Lucy J ^a   Herring, Chris ^a   Jespers, Laurent S ^b   Woolven, Benjamin P ^a   Tomlinson, Ian M ^a  

^a Domantis   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CELL CULTURE; DRUG PRODUCTS; MICROBIOLOGY; SOLUBILITY; THERMODYNAMIC STABILITY;

IMMUNOGLOBULINS;

ANTIBODIES;

ANTIBODY; DOMAIN ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTIBODY STRUCTURE; BINDING AFFINITY; CELL CULTURE; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; HUMAN; MICROORGANISM; MOLECULAR CLONING; MOLECULAR SIZE; NONHUMAN; PHAGE DISPLAY; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PICHIA PASTORIS; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REVIEW; SACCHAROMYCES CEREVISIAE;

CAMELIDAE; ESCHERICHIA COLI; NEGIBACTERIA; PICHIA; PICHIA PASTORIS; PLEURONECTIDAE; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

EID: 0142080390     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2003.08.007     Document Type: Review

References (74)

1. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
2. Ward E.S., et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 341:1989;544-546.
3. Hendershot L., et al. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J. Cell Biol. 104:1987;761-767.
4. Prelli F., Frangione B. Franklin's disease: Igγ2H chain mutant BUR. J. Immunol. 148:1992;949-952.
5. Hilschmann N., Criag L.C. Amino acid sequence studies with Bence-Jones proteins. Proc. Natl. Acad. Sci. U. S. A. 53:1965;1403-1409.
6. Ungar-Waron H., et al. Dromedary IgG: purification, characterisation and quantitation in sera of dams and newborns. Israel J. Vet. Med. 43:1987;198-203.
7. Arbabi Ghahroudi M., et al. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 414:1997;521-526.
8. Lauwereys M., et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 17:1998;3512-3520.
9. Roux K.H., et al. Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins. Proc. Natl. Acad. Sci. U. S. A. 95:1998;11804-11809.
10. H molecules with a unique interface. J. Mol. Biol. 290:1999;685-698.
11. H domains as small recognition units. Biotechnology. 13:1995;475-479.
12. van den Beucken T., et al. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J. Mol. Biol. 310:2001;591-601.
13. Marks J.D., et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:1991;581-597.
14. Griffiths A.D., et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:1994;3245-3260.
15. Pereira B., et al. Cardiolipin binding a light chain from lupus-prone mice. Biochemistry. 37:1998;1430-1437.
16. Spinelli S., et al. The crystal structure of a llama heavy chain variable domain. Nat. Struct. Biol. 3:1996;752-757.
17. Decanniere K., et al. A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Struct. Fold. Des. 7:1999;361-370.
18. H domains. FEBS Lett. 339:1994;285-290.
19. HH) from llama. Proteins Struct. Funct. Genet. 47:2002;546-555.
20. L interface. Biochemistry. 41:2002;8570-8579.
21. Decanniere K., et al. Canonical antigen-binding loop structures in immunoglobulins: more structures, more canonical classes? J. Mol. Biol. 300:2000;83-91.
22. H domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 7:1994;1129-1135.
23. Spinelli S., et al. Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry. 39:2000;1217-1222.
24. H antibody fragment in complex with lysozyme. Nat. Struct. Biol. 3:1996;803-811.
25. HH domains in complex with porcine pancreatic α-amylase. Inhibition and versatility of binding topology. J. Biol. Chem. 277:2002;23645-23650.
26. HH and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. 19:2000;921-930.
27. H domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng. 10:1997;607-614.
28. H domain of anti-neuraminidase antibody NC41. J. Protein Chem. 14:1995;167-178.
29. H domain into a more tractable species. J. Mol. Biol. 300:2000;963-973.
30. H domains: residues in all three hypervariable regions affect antigen binding. Immunotechnology. 2:1996;169-179.
31. H domain. J. Mol. Biol. 259:1996;957-969.
32. HH properties. J. Immunol. Methods. 263:2002;97-109.
33. Wu T.T., et al. Length distribution of CDRH3 in antibodies. Proteins Struct. Funct. Genet. 16:1993;1-7.
34. Tanha J., et al. Optimal design features of camelized human single-domain antibody libraries. J. Biol. Chem. 276:2001;24774-24780.
35. Ewert S., et al. Biophysical properties of human antibody variable domains. J. Mol. Biol. 325:2003;531-553.
36. H3 domains. Biochemistry. 41:2002;3628-3636.
37. HH antibody fragments and mouse monoclonal antibodies. Biochim. Biophys. Acta. 1431:1999;37-46.
38. Dumoulin M., et al. Single-domain antibody fragments with high conformational stability. Protein Sci. 11:2002;500-515.
39. Perez J.M., et al. Thermal unfolding of a llama antibody fragment: a two-state reversible process. Biochemistry. 40:2001;74-83.
40. Worn A., Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305:2001;989-1010.
41. H domains with a generalizable approach. Biochemistry. 42:2003;1517-1528.
42. H segments with different hypervariable loops. J. Mol. Biol. 227:1992;776-798.
43. H gene segments rearranged in vitro. J. Mol. Biol. 227:1992;381-388.
44. Winter G. Synthetic human antibodies and a strategy for protein engineering. FEBS Lett. 430:1998;92-94.
45. Jirholt P., et al. Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework. Gene. 215:1998;471-476.
46. Hawkins R.E., et al. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol. 226:1992;889-896.
47. Low N.M., et al. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol. 260:1996;359-368.
48. Hermes J.D., et al. A reliable method for random mutagenesis: the generation of mutant libraries using spiked oligodeoxyribonucleotide primers. Gene. 84:1989;143-151.
49. Marks J.D., et al. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology. 10:1992;779-783.
50. L-domain of monoclonal antibody F11. Biochemistry (Mosc.). 65:2000;1011-1018.
51. H domain of the mouse anti-ferritin antibody F11. FEBS Lett. 518:2002;177-182.
52. Clark E.D. Protein refolding for industrial processes. Curr. Opin. Biotechnol. 12:2001;202-207.
53. Joosten V., et al. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. Microbial Cell Factories. 2:2003;1.
54. HH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J. Biotechnol. 78:2000;11-21.
55. HH antibody fragments by Saccharomyces cerevisiae. Enzyme Microb. Technol. 30:2002;273-278.
56. van der Linden R.H., et al. Improved production and function of llama heavy chain antibody fragments by molecular evolution. J. Biotechnol. 80:2000;261-270.
57. Houdebine L.M. Antibody manufacture in transgenic animals and comparisons with other systems. Curr. Opin. Biotechnol. 13:2002;625-629.
58. Ivarie R. Avian transgenesis: progress towards the promise. Trends Biotechnol. 21:2003;14-19.
59. Stoger E., et al. Plantibodies: applications, advantages and bottlenecks. Curr. Opin. Biotechnol. 13:2002;161-166.
60. Jobling S.A., et al. Immunomodulation of enzyme function in plants by single-domain antibody fragments. Nat. Biotechnol. 21:2003;77-80.
61. Conrath K.E., et al. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J. Biol. Chem. 276:2001;7346-7350.
62. Cortez-Retamozo V., et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int. J. Cancer. 98:2002;456-462.
63. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer. 1:2001;118-129.
64. Chapman A.P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54:2002;531-545.
65. Peters T. Jr. Serum albumin. Adv. Protein Chem. 37:1985;161-245.
66. Smith B.J., et al. Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug. Chem. 12:2001;750-756.
67. Dennis M.S., et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277:2002;35035-35043.
68. Persic L., et al. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene. 187:1997;9-18.
69. Bender E., et al. Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. Hum. Antibodies Hybridomas. 4:1993;74-79.
70. Powers D.B., et al. Expression of single-chain Fv-Fc fusions in Pichia pastoris. J. Immunol. Methods. 251:2001;123-135.
71. Marks J.D., et al. Human antibody fragments specific for human blood group antigens from a phage display library. Biotechnology. 11:1993;1145-1149.
72. Muruganandam A., et al. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 16:2002;240-242.
73. Duenas M., Borrebaeck C.A. Clonal selection and amplification of phage displayed antibodies by linking antigen recognition and phage replication. Biotechnology. 12:1994;999-1002.
74. Kristensen P., Winter G. Proteolytic selection for protein folding using filamentous bacteriophages. Fold. Des. 3:1998;321-328.